Bivatuzumab

Bivatuzumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD44 v6
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
ATC code None
Chemical data
Formula  ?
 Y(what is this?)  (verify)

Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6.[1][2]

It is officially described as "immunoglobulin G1 (human-mouse monoclonal BIWA4 γ1-chain anti-human antigen CD44v6), disulfide with human-mouse monoclonal BIWA4 κ-chain, dimer".[3] Prior to 2002 it was described as targeting CD44 v8.[4]

It has been chemically linked to various radioisotopes for use in radiotherapy for, e.g. inoperable recurrent or metastatic head and neck cancer.[1]

It has also been linked to a cytotoxic drug mertansine to form bivatuzumab mertansine.

References

  1. ^ a b Postema et al. (2003). "Dosimetric Analysis of Radioimmunotherapy with 186Re-Labeled Bivatuzumab in Patients with Head and Neck Cancer.". http://jnm.snmjournals.org/cgi/content/abstract/44/10/1690. 
  2. ^ Börjesson et al. (2003). "Phase I Therapy Study with 186Re-labeled Humanized Monoclonal Antibody BIWA 4 (Bivatuzumab) in Patients with Head and Neck Squamous Cell Carcinoma.". http://clincancerres.aacrjournals.org/content/9/10/3961s.abstract. 
  3. ^ WHO Drug Information Vol. 16, No. 3, 2002
  4. ^ WHO Drug Information, Vol. 15, No. 1, 2001 Recommended INN: List 45. p4